Reported about 11 hours ago
ICON plc (ICLR) has seen a significant drop in its share value, losing 49.17% over the past year due to ongoing volatility in the clinical development market, which has affected client decisions and project timelines. Despite these challenges, the company is positioned to benefit from long-term growth in pharmaceutical R&D spending. Baron Funds highlighted ICON as a noteworthy stock in their Q2 2025 report, noting that its shares currently offer great value at half their previous trading multiples.
Source: YAHOO